• Growing clinical evidence supports the expanding role of mobile and home-based ECG capture in improving patient outcomes.
• HeartBeam’s proprietary system offers a cable-free design that allows for high-fidelity ECG measurements without the complexity of conventional equipment.
• Portable, credit card-sized design enables patients to record symptoms at home or wherever they are.

Clinicians are increasingly recognizing the value of accurate at-home electrocardiogram (“ECG”) capture, a development that is shaping the future of cardiac care. HeartBeam (NASDAQ: BEAT) is positioned at the forefront of this transformation with its FDA-cleared HeartBeam System, the first cable-free ECG device that captures the heart’s signals from 3 distinct directions and is designed to be a groundbreaking solution for at-home detection and monitoring of arrhythmias.

Growing clinical evidence supports the expanding role of mobile and home-based ECG capture in improving patient outcomes. A recent report indicates that UK doctors believe home ECG devices could soon save thousands of lives by enabling earlier identification of heart problems such as long QT syndrome and acute myocardial infarctions (https://ibn.fm/Y1eel).

This perspective is reinforced by a scoping “Heart Rhythm” review, which examined the performance of remote and wearable ECG systems for long-term rhythm monitoring (https://ibn.fm/zTdh3). The review found compelling evidence that these devices excel at detecting arrhythmias, particularly atrial fibrillation, in real-world use. In some cases, they outperformed standard 12-lead ECG systems for specific arrhythmias, reflecting the growing clinical acceptance of at-home ECG tools as reliable and valuable diagnostic resources.

Real-world adoption further validates the shift toward home-based cardiac monitoring. A study analyzing clinical correspondence revealed that in approximately 69% of cases, self-reported ECG data from home devices directly influenced treatment decisions (https://ibn.fm/Q5jA7). Physicians used these readings to confirm diagnoses, adjust medications and manage known conditions more effectively, underscoring the value of the readings in day-to-day patient care.

Together, these findings illustrate a broader trend: Accurate, home-based ECG systems are no longer viewed as experimental gadgets but as integral tools that complement traditional care. They are especially valuable for arrhythmia detection, post-event monitoring and early intervention, all areas where time and accuracy can be critical to patient outcomes.

HeartBeam’s proprietary system builds on this momentum by offering a unique, cable-free design that allows for high-fidelity measurements without the complexity of conventional equipment. Unlike standard devices that capture electrical signals from limited perspectives, HeartBeam’s patented approach records from three distinct angles, enabling a more complete view of the heart’s electrical activity. This expanded data capture is intended to improve diagnostic precision, particularly for arrhythmias that may be missed with traditional methods. Additionally, the patient can always have the device with them and take a recording at the time of symptom onset, potentially reducing any delays in care. 

In December 2024, HeartBeam received its foundational FDA clearance, marking a significant milestone for the company and opening the door for broader adoption in both clinical and consumer health settings. Regulatory approval not only validates the technology’s safety and effectiveness for arrhythmia assessment but also positions HeartBeam to enter new markets where remote monitoring is becoming a standard of care. In an era where healthcare is increasingly shifting toward decentralized, patient-managed models, the system’s ease of use and diagnostic capabilities align well with current trends in telemedicine and preventive care.

HeartBeam anticipates that the system will accelerate partnerships with healthcare providers, enabling physicians to extend high-quality cardiac assessment beyond the confines of the clinic for future approved uses. For patients, this means earlier detection of potentially life-threatening conditions, better management of chronic cardiac issues and greater convenience in monitoring heart health without frequent office visits.

As demand for accurate, at-home cardiac diagnostics continues to grow, fueled by both clinical evidence and patient preference, HeartBeam’s innovative technology is poised to play a pivotal role in reshaping cardiac care. The HeartBeam System’s combination of precision, accessibility and foundational regulatory clearance represents a timely solution to one of medicine’s most pressing needs: getting critical diagnostic data into the hands of clinicians when it matters most.

For more information, visit www.HeartBeam.com.

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

• ESGold CEO Gordon Robb recently appeared in an interview on an “Inside the Boardroom” webcast, with an episode featuring insights on the company’s non-traditional production-first revenue model
• The company is nearing the launch date for beginning tailings recovery at an abandoned legacy mine west of Quebec’s capital city, where ESGold is 100% permitted to extract value metals such as gold and silver while improving the environment at the site
• The tailings recovery effort is a near-term revenue generation strategy that allows the company to boost its coffers from the production cycle first, opening the door to eventual exploration efforts without having to seek investor capital raises to continue forward
• ESGold is also beginning to evaluate the potential of some of the hundreds of additional similar sites throughout North and South America

Sustainable gold mining innovator ESGold (CSE: ESAU) (OTCQB: ESAUF) offers its shares as an affordable way, with better return prospects, for investors to ride the gold waves, and sees the company’s revenue model as a savvy approach to capitalization without having to continually ask for investors for new infusions. Gold has enjoyed generally upward market movement this year, rising at a modest pace during the summer after more pronounced gains during the opening months of 2025.

The company’s beneficial revenue model entails reclaiming mines polluted with toxic wastes left over from prior exploration, and repurposing value metals from the tailings to be used in clean building work projects. ESGold’s fully permitted ownership of eastern Canada’s Montauban project is serving as the company’s proof of concept.

“Because this was a past producing mine, there’s a lot of toxic tailings left around the surface of this project, including the (nearby) township. Our main focus is to go in to clean up that toxic liability while extracting the economic value — the gold and silver and mica left in those tails,” ESGold CEO Gordon Robb said during an interview this month with the “Inside the Boardroom” webcast (https://nnw.fm/yCUbz) (https://ibn.fm/zwOJx).

Setup is nearly complete on the facilities for the mill circuit and related assembly to begin reprocessing the tailings, and the company anticipates the potential to generate close to $350 million from tailings and near surface hard rock during the coming decade — generating revenue that can be reinvested in future exploration.

“Our main focus is to get this up and running, to be able to generate cash flow from those tailings, and then funnel that capital into the exploration,” Robb said. “Essentially we’re reverse-engineering that model. Rather than exploration-development-production, we’re going production first and then (we’ll) be able to have non-dilutive funding to go into building this out at scale and having potentially a district-scale discovery.”

ESGold regards Montauban as a previously under-explored site and has begun assessing its potential for producing additional precious metals. The company conducted a non-invasive Ambient Noise Tomography (“ANT”) survey using sound waves to reveal that the mineral system remains open at depth vertically and laterally, meaning the geological makeup of the below-ground area is conducive to gold and silver formation (https://nnw.fm/kqKAZ) (https://ibn.fm/NR9jf).

ESGold is also examining the potential of other abandoned sites for similar recovery and revenue generation throughout North and South America. U.S. environmental statistics report more than 500,000 abandoned mine sites exist in North America, many of which contain tailings piles with residual precious and base metals awaiting evaluation. South America has an even larger number of potential sites after decades of small- to mid-scale mining operations in gold-rich areas of Peru, Bolivia, Colombia and Chile (https://nnw.fm/O1Krh) (https://ibn.fm/8Jzxs).

“There’s an enormous untapped economic and environmental opportunity here,” company COO and Chairman Paul Mastantuono stated.

For more information, visit the company’s website at https://esgold.com.

NOTE TO INVESTORS: The latest news and updates relating to ESAUF are available in the company’s newsroom at https://nnw.fm/ESAUF https://ibn.fm/ESAUF

• British Columbia’s mining regulatory environment represents one of the most comprehensive frameworks in global mining.
• Nicola Mining’s success in leveraging BC’s regulatory framework demonstrates how strategic compliance creates sustainable competitive advantages.
• The company’s commitment to regulatory excellence extends beyond minimum requirements to include environmental stewardship, community engagement.

While some mining companies view regulatory compliance as a necessary cost of doing business, forward-thinking operators recognize that British Columbia’s well-structured regulatory framework creates significant competitive advantages and unlocks hidden value opportunities in one of North America’s most prolific mining jurisdictions. Nicola Mining (TSX.V: NIM) (OTCQB: HUSIF) exemplifies this strategic approach as a junior resource company that has successfully leveraged BC’s clear regulatory pathways to build a dual-pronged business model.

British Columbia’s mining regulatory environment represents one of the most comprehensive frameworks in global mining, designed to balance economic development with environmental stewardship and Indigenous reconciliation (https://ibn.fm/mnqf0). The province takes responsible mining seriously, with mining projects guided by regulatory requirements based on evidence, continuous improvement, and best practices throughout the mining lifecycle. This rigorous approach ensures that mining projects meet strict requirements that protect health, safety and the environment from initial exploration through production, reclamation and closure, applying to all mineral, coal, placer, sand, gravel, and quarry operations across the province.

The regulatory framework’s strength lies in its integration of multiple stakeholder interests through structured processes that, while demanding, create predictability and long-term operational security for compliant operators. Mining regulatory processes include ongoing collaboration with First Nations to help achieve the best possible outcomes, reflecting the province’s commitment to Indigenous reconciliation and meaningful consultation (https://ibn.fm/xgEYY).

The province’s regulatory evolution demonstrates a sophisticated understanding of modern mining challenges, particularly around critical minerals and climate change adaptation. Low-carbon technologies demand critical minerals, and with increased global demand (https://ibn.fm/Env5m), long-term shortages are predicted, positioning British Columbia’s developing critical minerals strategy as both an economic opportunity and a climate change mitigation tool. The province’s regulatory framework is designed to support this transition while ensuring that increased mining activity meets the highest environmental and social standards.

British Columbia’s commitment to regulatory excellence extends beyond compliance to encompass continuous improvement and technological innovation. The province remains a world leader in mine health and safety practices, with mining recognized as one of British Columbia’s safest heavy industries. This safety leadership stems from comprehensive regulatory oversight supported by specialized units like the Mine Audits Unit, which plays a key role in supporting the continuous improvement of mining regulation and oversight throughout the province.

Nicola Mining’s success in leveraging British Columbia’s regulatory framework demonstrates how strategic compliance creates sustainable competitive advantages in complex jurisdictions. The company’s operations at the New Craigmont Copper Project showcase effective regulatory management, with the Craigmont property composed of 10 mineral leases and 22 mineral claims strategically positioned just 14 kilometers from the city of Merritt via paved road access (https://ibn.fm/3Fzkw). This infrastructure, comprising maintained dirt roads and numerous tracks, reflects the kind of long-term operational foundation that regulatory compliance enables in British Columbia.

The company’s dual permit structure exemplifies how regulatory mastery translates into operational flexibility and strategic positioning. Nicola Mining holds both a 10-year mining lease extension and a 5-year exploration permit, creating a position that enables systematic exploration of high-grade surface samples while maintaining operational capabilities. This regulatory foundation supports the company’s unique business model of combining immediate revenue generation through its gold and silver milling operations with long-term value creation through copper, silver and gold exploration across its extensive land package.

Nicola Mining’s environmental compliance initiatives illustrate how regulatory requirements drive innovation and create additional revenue opportunities. The company has received permits allowing it to receive Trans Mountain material for remediation purposes, with all imported material tested to assure environmental compliance (https://ibn.fm/p4gAK). This capability transforms regulatory requirements into business opportunities while advancing environmental restoration objectives, exemplifying how sophisticated operators turn compliance into competitive advantage.

The company’s commitment to regulatory excellence extends beyond minimum requirements to encompass proactive environmental stewardship and community engagement. Nicola Mining’s approach to land reclamation utilizes native grass seed mixes recommended by local ranchers and First Nation advisors, reviewed by qualified environmental professionals to ensure ecological compatibility (https://ibn.fm/puOJS). This collaborative approach reflects the kind of stakeholder engagement that British Columbia’s regulatory framework encourages and rewards.

Nicola Mining’s success in British Columbia illustrates how junior mining companies can transform regulatory complexity into strategic advantage through comprehensive compliance, stakeholder engagement and innovative operational approaches. The company’s ability to maintain both immediate revenue generation and long-term exploration potential reflects the kind of operational flexibility that mastering British Columbia’s regulatory framework enables.

The province’s regulatory environment, rather than representing a barrier to development, creates opportunities for savvy operators to build sustainable competitive advantages through compliance excellence, stakeholder collaboration and environmental stewardship. Companies such as Nicola Mining demonstrate that regulatory mastery enables not just operational success, but the creation of unique business models that generate value across multiple timeframes and stakeholder groups.

For more information, visit www.NicolaMining.com.

NOTE TO INVESTORS: The latest news and updates relating to HUSIF are available in the company’s newsroom at https://ibn.fm/HUSIF

• Proceeds will support commercialization of Safe Pro’s AI-powered defense and security technologies, including SPOTD and NODE, and could expand to $20 million through warrant exercises.
• The company’s AI has processed 1.78 million drone images in Ukraine, detecting over 31,600 explosive threats.
• Expanding military budgets for drones and AI, alongside global demining needs, highlight a strong and growing market opportunity.

Safe Pro Group (NASDAQ: SPAI), an emerging provider of drone-based AI-powered security and threat detection solutions, has closed an $8 million private placement with strategic investors Ondas Holdings Inc. (NASDAQ: ONDS) and Unusual Machines Inc. (NYSE: UMAC), both leaders in the drone sector. The deal includes the sale of 2 million shares at $4.00 per share, alongside warrants for another 2 million shares at an exercise price of $6.00 (https://ibn.fm/tKMTs).

If exercised in full, the package could bring Safe Pro up to $20 million in new capital. Financial advisors Northland Capital Markets and Dawson James Securities oversaw the transaction.

Proceeds from the placement will help Safe Pro commercialize its artificial intelligence technologies, including the Safe Pro Object Threat Detection (“SPOTD”) system and its Navigation Observation Detection Engine (“NODE”). Both are designed to enhance situational awareness by leveraging proprietary AI-powered image analysis for rapid threat identification and off-the-shelf drones.

SPOTD can detect more than 150 types of explosive hazards, such as landmines and unexploded ordnance. The system operates either locally on Windows-based laptop or remotely in the Cloud via Amazon Web Services, giving operators flexibility in deployment.

Safe Pro’s technology has already been tested in high-stakes environments. In Ukraine, the SPOTD technology has already processed more than 1.78 million high-resolution drone images, identifying over 31,600 explosive threats across nearly 7,819 hectares (19,321 acres).

The company argues this real-world dataset strengthens the accuracy of its AI models and gives Safe Pro an advantage as it moves from pilot projects toward commercialization, and Safe Pro’s capabilities have already drawn interest from the U.S. Army. The company has been selected to participate in two demonstrations at the Army Futures Command’s 2026 Concept Focused Warfighter Experiment (the Maneuver event and the Live Breach event).

These tests will demonstrate how Safe Pro’s AI can identify threats in a fraction of a second per image and integrate detections into systems such as the Tactical Assault Kit (“TAK”) ecosystem. TAK is widely used across U.S. and allied military forces, suggesting Safe Pro’s tools could become part of small unit operations if adopted.

Recent defense funding trends could also work in Safe Pro’s favor. The U.S. Senate Appropriations Committee has advanced a proposal allocating $617 million to small unmanned aircraft systems, including programs directly aligned with Safe Pro’s operational focus. In addition, the “One Big Beautiful Bill Act” earmarks up to $30 billion for drones, AI, and modernization projects.

The potential customer base extends beyond defense. Nearly 60 countries face challenges from landmines or unexploded ordnance, highlighting opportunities in humanitarian demining and reconstruction. Infrastructure development in post-conflict areas could also benefit from AI-assisted detection and clearance capabilities such as the ones offered by Safe Pro.

For more information, visit the company’s website at www.SafeProGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to SPAI are available in the company’s newsroom at https://ibn.fm/SPAI

Octane, Southern California’s leading accelerator for technology and medical innovation, will host its Cardiovascular Tech Forum 2025 on September 11–12 at VEA Newport Beach, A Marriott Resort & Spa. The two-day forum will unite industry leaders, entrepreneurs, physicians, and investors to explore the future of cardiovascular innovation and shape the next generation of patient care.

The forum will feature a keynote address from Dr. John B. Simpson, PhD, MD, a pioneering interventional cardiologist and serial entrepreneur who invented the over-the-wire balloon angioplasty catheter, a groundbreaking advancement that transformed cardiovascular treatment. Dr. Simpson has founded seven companies, including Advanced Cardiovascular Systems, Devices for Vascular Intervention, and Perclose, all of which were acquired by leading strategics. His contributions have earned him global recognition, including the ESC Andreas Gruentzig Award, the TCT Lifetime Achievement Award, and the National Academy of Engineering’s Russ Prize.

Attendees will gain access to innovation panels highlighting the latest technologies and research, investment opportunities with high-potential companies vetted by Octane’s Capital & Growth team, and exclusive physician/entrepreneur sessions where early-stage ventures seek advisory, board members, and medical expertise. Beyond the program, the forum offers extensive networking opportunities, providing a vibrant hub where physicians, strategics, and capital providers can connect with entrepreneurs advancing breakthrough solutions in cardiovascular health.

Since its inception, Octane has helped accelerate hundreds of companies, fostering billions in investment capital and driving measurable growth across the medtech sector. The Cardiovascular Tech Forum continues this mission, catalyzing collaboration to advance life-saving technologies and expand access to cutting-edge care.

Registration is now open. Investors and physicians can secure their place at no cost by reaching out to info@octaneoc.org, while other industry related organizations can leverage opportunities to elevate their brand presence during the event. Attendees are also invited to take advantage of exclusive room rates at the VEA Newport Beach by booking through Octane’s event site.

To learn more or register, please visit: https://ibn.fm/BqI2u

• The company’s rebranding reflects Izotropic’s refined corporate positioning and emphasizes its focus on key people across the healthcare ecosystem
• Izotropic’s strategic positioning becomes even more critical when considering the magnitude of the opportunity ahead
• Izotropic has the exclusive global licensing rights to breast CT technology, and IzoView is the commercial model

As Izotropic (CSE: IZO) (OTCQB: IZOZF) positions itself to capture a share of the $8.7 billion global breast imaging market projected by 2030 (ibn.fm/tRIr4), the company has unveiled a strategic brand transformation that signals its readiness to commercialize two decades of breakthrough medical research. Izotropic holds exclusive global licensing rights to revolutionary breast CT technology and is advancing its flagship IzoView Breast CT Imaging System from proven science to real-world medical impact, offering what could be the first-in-class solution for more accurate breast cancer screening and diagnosis.

The company’s redesigned website reflects Izotropic’s refined corporate positioning and introduces a modern, unique, visual identity that emphasizes its focus on key people — patients, clinicians and stakeholders — across the healthcare ecosystem. This strategic transformation represents a pivotal moment for the company as it transitions from development to market readiness, requiring a brand presence that can effectively communicate its value proposition to diverse stakeholders across the global healthcare landscape.

The rebranding effort centers around establishing Izotropic as a leader in advanced breast imaging technology, with the company introducing a compelling corporate tagline that encapsulates its mission. “Advanced Imaging. Accessible Care.” appears in materials and corporate communications to communicate the Izotropic’s commitment to innovations that can scale across diverse care settings. This messaging directly addresses one of the most significant challenges in modern healthcare: making advanced diagnostic technologies accessible beyond traditional academic medical centers and major hospital systems.

Izotropic’s strategic positioning becomes even more critical when considering the magnitude of the opportunity ahead. The global breast imaging market is projected to reach approximately $8.7 billion by 2030, driven by demand for earlier, more accurate cancer detection. The company’s unique position in this expanding market stems from its exclusive licensing rights to proven technology that has undergone extensive development and validation.

The foundation of Izotropic’s commercial strategy rests on two decades of scientific advancement and clinical validation. Breast CT technology has been built, tested and refined in clinical trials for academic research purposes over the last 20 years. Izotropic has the exclusive global licensing rights to breast CT technology, and IzoView is the commercial model. This extensive development history provides the company with a significant competitive advantage, as the underlying technology has already demonstrated its clinical utility through rigorous academic research.

The company’s flagship product, the IzoView Breast CT Imaging System (ibn.fm/KTPtI), has received its own distinctive positioning within the broader brand architecture. The company’s flagship product, the IzoView system, carries a new distinct tagline: Engineered for Today’s Challenges and Tomorrow’s Care Models. The new tagline highlights the system’s ability to address unmet needs in breast imaging, while capturing its alignment with evolving industry trends driving market expansion. This product-specific messaging recognizes that healthcare systems are undergoing rapid transformation, with increasing emphasis on value-based care, improved patient outcomes and operational efficiency.

The comprehensive website redesign serves as more than just a digital facelift; it represents a strategic communication platform designed to support the company’s commercialization objectives. The site provides an accessible, centralized platform for engaging with Izotropic’s story, solutions and strategy as the company builds toward commercialization. The enhanced digital presence features multiple content types designed to engage different stakeholder groups, each with distinct information needs and decision-making processes.

Content enrichment has been a key focus of the rebranding initiative, with the company developing materials specifically designed to communicate complex medical technology in accessible terms. The updated web presence features streamlined navigation and enriched content, including new presentations, video materials and messaging that communicates Izotropic’s value proposition, clinical direction and strategic focus. This multimodal approach recognizes that different stakeholders prefer different types of information consumption, from detailed technical specifications for clinical researchers to accessible overviews for potential investors.

The leadership team driving this transformation brings together expertise across multiple critical disciplines required for successful medical device commercialization. Izotropic is led by a multidisciplinary team of experts in medical imaging, clinical research, engineering, and commercialization. Together, they are advancing IzoView from proven science to real-world impact. This diverse skill set is essential for navigating the complex regulatory, clinical, and commercial challenges inherent in bringing innovative medical devices to market.

The timing of this rebranding initiative reflects Izotropic’s strategic preparation for the next phase of its corporate development. As the company works toward regulatory approvals and commercial launch, having a professional, cohesive brand presence becomes increasingly important for stakeholder engagement, partnership development, and market positioning. The healthcare industry, in particular, demands high levels of professionalism and credibility from technology providers, making brand perception a critical component of commercial success.

The rebranding also positions Izotropic to better communicate its unique value proposition in an increasingly competitive landscape. With a first-in-class device and a focused clinical strategy, Izotropic offers a unique opportunity to invest at the forefront of a fast-growing sector. This position emphasizes both the innovative nature of the company’s technology and its strategic approach to market entry, appealing to investors seeking exposure to transformative healthcare technologies.

Looking ahead, the refreshed brand identity provides Izotropic with a foundation for sustained growth and market expansion. Izotropic invites investors, media, and stakeholders to explore the new site and follow the Company’s progress as it works to deliver transformative solutions to the global breast imaging market. This invitation represents more than marketing language; it reflects the company’s confidence in its technology, strategy, and ability to execute on its commercial objectives.

The comprehensive rebranding initiative demonstrates Izotropic’s commitment to professionalization and market readiness as it advances toward commercialization of its revolutionary breast imaging technology. Through strategic positioning, enhanced digital presence, and clear messaging, the company has established a brand foundation capable of supporting its ambitious growth objectives in the expanding global breast imaging market.

For more information, visit the company’s website at www.IzoCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to IZOZF are available in the company’s newsroom at ibn.fm/IZOZF

• The U.S. remains heavily dependent on China for rare earth processing and refined components critical to defense, electronics and clean-energy applications.
• An independent evaluation confirmed that RapidSX can separate both light and heavy REEs using proven conventional chemistry but dramatically faster kinetics. 
• Ucore’s broader vision includes disrupting China’s control over the REE industry by introducing scalable, high-efficiency separation technology.

The race to secure rare earth elements has become a matter of both economic survival and national security for the United States, as China continues to dominate the global supply chain for these critical resources. At the center of America’s push to break free from this dependence is Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF), whose RapidSX(TM) technology offers a faster, more efficient way to separate rare earths and build a resilient domestic supply chain.

The U.S. remains heavily dependent on China for rare earth processing and refined components critical to defense, electronics and clean-energy applications. China currently refines about 90% of the world’s rare earths, giving it outsized influence over the global supply chain (https://ibn.fm/1itJK). The country also dominates the critical permanent magnet market, producing an estimated 85–90% of global supply as of 2023 (https://ibn.fm/s8iMr). These magnets are essential for technologies ranging from electric vehicles to wind turbines, making China’s dominance a major strategic concern for U.S. policymakers and industry leaders. 

In addition, the United States doesn’t have adequate refining infrastructure. China processes nearly all heavy rare earths and most light rare earth refining, meaning the U.S. must export raw ore for processing and then re-import refined products. This highlights the critical need for Ucore and its RapidSX technology (https://ibn.fm/qSw3u). Ucore’s proprietary tech is a patent-pending, environmentally friendly, column-based solvent extraction process that separates both light and heavy REEs more efficiently and with a smaller footprint than traditional mixer-settler solvent extraction systems.

An independent evaluation by AGHS, commissioned by Ucore, confirmed that RapidSX can separate both light and heavy REEs using proven conventional chemistry but dramatically faster kinetics. This enables a potential two to three times smaller plant footprint and a more than 50% reduction in capital costs, with operating cost savings of about 20% compared to traditional processes, all while being scalable from 1,000 to more than 10,000 tonnes per annum (https://ibn.fm/3YPiR).

At the demonstration scale, RapidSX is already in action. Ucore operates a RapidSX Commercial Demonstration Plant in Kingston, Ontario, funded in part through a U.S. Department of Defense (“DoD”) contract valued at $4 million (https://ibn.fm/NAShw). The company has also secured an additional C$4.28 million from the government of Canada to support commercialization of RapidSX using North American feedstocks.

Ucore’s strategy extends to the U.S., with its planned Louisiana Strategic Metals Complex (“SMC”) in Alexandria, which aims to process both heavy and light mixed rare earth concentrates for North American supply resilience. Automation plays a key role, as RapidSX utilizes programmable logic controllers and hundreds of sensors in its 52-stage demonstration platform to enable precise, efficient operations (https://ibn.fm/89gwC).

Ucore’s broader corporate vision emphasizes disrupting China’s nearly complete control over the REE industry, particularly the $15.7 billion-per-year rare earth oxide supply chain, by introducing scalable, high-efficiency separation technology to North America (https://ibn.fm/7Hpzy). The company’s focus on scalable extraction, beneficiation and separation technologies positions it as an advanced-technology contributor in the critical metals sector.

China’s recent export restrictions on seven key medium and heavy rare earth elements—including samarium, terbium, and dysprosium—have further illuminated the urgency of establishing an independent U.S. supply chain. Ucore CEO Pat Ryan, P.Eng., emphasized that these developments highlight the “urgent need for a robust and independent rare earth supply chain in North America” and that RapidSX offers a transformative solution to the challenge.

By providing a viable path toward smaller, faster, more cost-effective REE separation that is backed by independent evaluation, automation and government support, RapidSX helps fill a glaring gap in the U.S. industrial ecosystem. Its modular design offers flexibility and scalability, making it well-suited not only for the Louisiana SMC but future strategic metals complexes in Canada and Alaska and even for proprietary feed sources such as Ucore’s Bokan-Dotson Ridge project.

For more information, visit www.Ucore.com.

NOTE TO INVESTORS: The latest news and updates relating to UURAF are available in the company’s newsroom at https://ibn.fm/UURAF

• The three projects, Sydney, Brooklyn, and Petpeswick, will generate a combined 12.4 MW DC of clean energy.
• Funding is provided by Nova Scotia’s Department of Energy and managed by Net Zero Atlantic.
• PowerBank is the lead developer for the owner, working alongside local partner Trimac Engineering.
• The projects are part of Canada’s first Community Solar Program, targeting 80% renewable energy by 2030.
• PowerBank has completed over 100 MW of projects and holds a pipeline exceeding 1 GW across North America.

Disseminated on behalf of PowerBank Corporation

PowerBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2), a premier developer and owner of renewable and clean energy projects, specializing in distributed and community solar initiatives throughout Canada and the U.S., secured $1.74 million in government funding to support three community solar projects across Nova Scotia. According to the company’s announcement, the Sydney, Brooklyn, and Petpeswick projects, once operational, will generate a total of 12.4 megawatts (“MW”) of direct current (“DC”) electricity, feeding clean power directly into the local grid (https://ibn.fm/e9gKm).

The funding is being distributed under the Nova Scotia Department of Environment and Climate Change, administered by the Department of Energy and managed by Net Zero Atlantic. The breakdown of funding is as follows:

• $340,000 for the Sydney Solar Project
• $440,000 for the Petpeswick Solar Project
• $960,000 for the Brooklyn Solar Project

Ownership of the projects is shared between AI Renewable Flow-through Fund (48%) and non-profit or Indigenous partners such as the Potlotek First Nation (52%). PowerBank will act as lead developer and builder, partnering with Trimac Engineering, a Nova Scotia-based firm.

The projects fall under the Nova Scotia Community Solar Program (“CSP”), the first of its kind in Canada. The program supports the province’s goal of generating 80% of electricity from renewable sources by 2030 and achieving a net-zero grid by 2035.

Through CSP, community members, including renters and businesses, can subscribe to local solar projects and receive credits on their electricity bills, typically saving around $0.02 per kilowatt-hour (“kWh”). This model makes solar accessible without the need for installing panels on homes or commercial properties.

The initiative is also expected to stimulate local economic activity by supporting engineering, construction, and long-term operations within the province.

For PowerBank, the grant underscores its strategy of expanding beyond U.S. markets into Canada. PowerBank positions itself as a high-growth renewable energy developer. To date, the company has completed more than 100 MW of solar capacity and is advancing a development pipeline of over one gigawatt. Its portfolio spans distributed and community solar, as well as battery energy storage systems (“BESS”).

The company has already delivered over 100 MW of community solar projects in the United States and sees Nova Scotia as a key growth opportunity as community solar programs develop across Canada. Dr. Richard Lu, President and CEO of PowerBank, said the funding will help ensure the long-term success of these initiatives:

“This funding from Net Zero Atlantic will go far towards the development of long-lasting solar projects that bring clean energy and energy savings to Nova Scotia,” said Dr. Lu. “With over a decade of proven experience in solar development and operations—including community solar, commercial and industrial installations, and other government-led initiatives—PowerBank brings the expertise needed to the successful implementation of Nova Scotia’s Community Solar projects.”

For more information, visit the company’s website at https://PowerBankCorp.com.

This report contains forward looking information. Please refer to the press release entitled “Community Solar Projects Receive $1.74 Million Grant from Net Zero Atlantic” and dated August 19, 2025, for additional details on the information, risks and assumptions.

NOTE TO INVESTORS: The latest news and updates relating to SUUN are available in the company’s newsroom at https://ibn.fm/SUUN

• CEO reports confidence about late-stage rare disease pipeline and upcoming key development milestones.
• Soligenix’s recent accomplishments reflect substantial momentum across its specialized biotherapeutics and public health solutions business segments.
• The company’s pipeline diversification strategy extends beyond CTCL treatment to encompass multiple therapeutic areas.

With pivotal phase 3 cancer trial results due in 2026 and multiple fast-tracked therapies advancing through late-stage development, Soligenix (NASDAQ: SNGX) stands at the threshold of potentially transforming treatment paradigms for rare diseases affecting millions of underserved patients worldwide. The Soligenix pipeline includes a novel photodynamic drug therapy, along with other innovative drug and vaccine technology, to tackle medical challenges where conventional treatments have failed to deliver meaningful solutions, recently reported on its progress so far this year (https://ibn.fm/1dhGj).

“As we quickly approach the latter part of 2025 into 2026, the company remains confident about its late-stage rare disease pipeline and upcoming key development milestones,” said Soligenix CEO and president Christopher J. Schaber in the update. “These include top-line results from our phase 2a clinical trial in mild-to-moderate psoriasis with SGX302 (synthetic hypericin) before year end, as well as continued clinical update for the ongoing investigator-initiated study (‘IIS’) evaluating extended HyBryte(TM) (synthetic hypericin) treatment for up to 54 weeks in patients with early-stage cutaneous T-cell lymphoma (‘CTCL’).

“Further, we anticipate top-line results in 2026 from our actively enrolling confirmatory phase 3 study of HyBryte for early-stage CTCL, where we plan to provide an enrollment update later this year,” Schaber continued. “Recently, we were also pleased to announce the successful completion of our phase 2a proof of concept study evaluating SGX945 (dusquetide) in the treatment of Behçet’s disease, having achieved the study objective of demonstrating biological efficacy in this difficult to treat chronic disease.”

The company’s recent accomplishments reflect substantial momentum across its specialized biotherapeutics segment, positioning Soligenix at a critical inflection point in its development trajectory. The most significant advancement centers on the company’s flagship HyBryte (“SGX301” or synthetic hypericin sodium) program, which represents a novel photodynamic therapy utilizing safe visible light for the treatment of CTCL. This innovative approach addresses a significant unmet medical need in oncology, where traditional treatment options remain limited and often associated with substantial side effects.

The clinical promise of HyBryte extends beyond initial efficacy data to encompass sustained therapeutic benefits that distinguish it from existing treatment options. Analysis of post-treatment data from the open-label study comparing HyBryte to Valchlor(R) (mechlorethamine) demonstrated continued improvement in HyBryte-treated patients and their individual lesions even after stopping treatment. This durability of response represents a significant clinical advantage, potentially reducing treatment burden and improving quality of life for patients with this challenging condition.

Soligenix’s commitment to comprehensive clinical development is further demonstrated through the formation of a European Medical Advisory Board in November 2024 (https://ibn.fm/yzssW). This strategic initiative provides additional medical and clinical guidance as the company advances its confirmatory phase 3 multicenter, double-blind, placebo-controlled study. The international expertise represented by this advisory board reflects the global commercial potential of HyBryte and the company’s intention to pursue regulatory approvals across multiple jurisdictions.

The company’s pipeline diversification strategy extends beyond CTCL treatment to encompass multiple therapeutic areas through its synthetic hypericin technology platform. The expansion of synthetic hypericin (“SGX302”) into psoriasis treatment represents a significant market opportunity, with mild-to-moderate psoriasis affecting millions of patients worldwide (https://ibn.fm/qruXo). The ongoing phase 2 study in this indication, with top-line results anticipated in the second half of 2025, could unlock substantial additional commercial potential for the synthetic hypericin platform.

The financial foundation supporting these clinical initiatives reflects disciplined capital allocation while maintaining sufficient runway for critical development milestones. With approximately $6.5 million in cash as of July 1, 2025, the company has secured operating runway through the first quarter of 2026, enabling completion of several pivotal clinical milestones without immediate financing pressure. This financial position provides strategic flexibility as the company evaluates partnership opportunities, merger and acquisition possibilities, government grants, and potential financing options to advance its late-stage pipeline.

The company’s revenue structure reflects its dual business model, combining clinical development activities with government-funded programs supporting national biodefense initiatives. While revenues decreased to $0.1 million for 2024 compared to $0.8 million in the prior year, this fluctuation primarily reflects the timing of government grant funding rather than fundamental program changes. The company continues to receive government funding for its public health solutions segment, which includes vaccine development programs targeting critical national security threats.

Research and development expenses increased to $5.2 million in 2024 compared to $3.3 million in the prior year, reflecting the company’s commitment to advancing multiple clinical programs simultaneously. The increase primarily related to preliminary costs associated with the Behçet’s Disease Phase 2 study initiation and the second confirmatory Phase 3 CTCL trial, demonstrating active progress across the development pipeline.

The strategic positioning of Soligenix’s pipeline addresses multiple high-value therapeutic areas with significant unmet medical need. The combination of novel photodynamic therapy technology, innovative vaccine platforms, and first-in-class inflammatory disease treatments creates a diversified portfolio with multiple paths to commercial success and substantial value creation potential.

Looking ahead, the company anticipates several critical inflection points that could significantly impact valuation and strategic positioning. The expected top-line results from multiple phase 2 studies in the second half of 2025, combined with ongoing phase 3 CTCL trial progress toward 2026 readout, provide multiple near-term catalysts for value creation and potential partnership opportunities.

For investors and stakeholders seeking exposure to innovative rare disease therapeutics with significant commercial potential, Soligenix’s current positioning represents a compelling opportunity at a critical development inflection point, supported by a diversified pipeline addressing multiple high-value therapeutic areas.

For more information, visit www.Soligenix.com.

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX

• GlobalTech balances internal innovation with strategic acquisitions to accelerate growth and long-term value creation.
• The company’s flagship platforms span multiple high-growth domains including enterprise productivity, e-commerce, digital lending, and compliance.
• Its majority stake in WorldCall Telecom Ltd. supports infrastructure-led value creation in Pakistan’s telecommunications sector.
• Strategic alliances with regional players such as Omantel anchor GlobalTech’s expansion into key international markets like the Middle East.

GlobalTech (OTC: GLTK) is a U.S.-based technology holding company specializing in artificial intelligence (“AI”), big data, and digital infrastructure. Advancing toward a Nasdaq listing, the company balances internal innovation with strategic acquisitions to accelerate growth and long-term value creation.

GlobalTech’s diversified portfolio spans AI-powered solutions for enterprise productivity, e-commerce, retail, digital lending, compliance, and other high-growth domains. Flagship platforms include ThrivoAI, Cadnz, Baseball Blitz, Talina, ProtoEd, BillCare, Giftio, and EntityScan. The company also holds a majority stake in WorldCall Telecom Ltd., extending its telecommunications presence in Pakistan and supporting infrastructure-led value creation.

To strengthen market reach, GlobalTech continues to evaluate technology-centric acquisitions while also expanding through strategic regional alliances. Its partnership with significant regional players like Omantel anchors growth in the Middle East, a key gateway market. At the same time, the company’s Center of Excellence (“CoE”) and #GTCTalks knowledge platform position it as a thought leader in emerging technologies.

Supported by a seasoned leadership team and a disciplined execution model, GlobalTech is building sustainable momentum across global AI and big data markets, with the governance, innovation, and agility required to capture outsized opportunities in the digital economy.

For more information, visit the company’s website at www.GlobalTechCorporation.com.

NOTE TO INVESTORS: The latest news and updates relating to GLTK are available in the company’s newsroom at https://ibn.fm/GLTK